Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia

E. Tsitsikov, M. H. Harris, L. B. Silverman, S. E. Sallan, O. K. Weinberg

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Introduction: Minimal residual disease (MRD) in B lymphoblastic leukemia has been demonstrated to be a powerful predictor of clinical outcome in numerous studies in both children and adults. In this study, we evaluated 86 pediatric patients with both diagnostic and remission flow cytometry studies and compared expression of CD81, CD58, CD19, CD34, CD20, and CD38 in the detection of MRD. Methods: We evaluated 86 patients with B lymphoblastic leukemia who had both diagnostic studies and remission studies for the presence of MRD using multicolor flow cytometry. We established our detection limit for identifying abnormal lymphoblasts using serial dilutions. We also compared flow cytometry findings with molecular MRD detection in a subset of patients. Results: We found that we can resolve differences between hematogones and lymphoblasts in 85 of 86 cases using a combination of CD45, CD19, CD34, CD10, CD20, CD38, CD58, and CD81. Our detection limit using flow cytometry is 0.002% for detecting a population of abnormal B lymphoblasts. Comparison with MRD assessment by molecular methods showed a high concordance rate with flow cytometry findings. Conclusions: Our study highlights importance of using multiple markers to detect MRD in B lymphoblastic leukemia. Our findings indicate that including both CD58 and CD81 markers in addition to CD19, CD34, CD20, CD38, and CD10 are helpful in MRD detection by flow cytometry.

Original languageEnglish (US)
Pages (from-to)343-351
Number of pages9
JournalInternational Journal of Laboratory Hematology
Issue number3
StatePublished - Jun 2018
Externally publishedYes


  • ALL
  • flow cytometry
  • general hematology
  • minimal residual disease

ASJC Scopus subject areas

  • Hematology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this